LBA85 TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of Oncology

Topics

Computer Science

Cancer Oncology

Medicine

Internal Medicine

Urology

Show all topics

DOI

10.1016/j.annonc.2024.08.2329